ask our doctors

Tardive Dyskinesia

Get the facts on Tardive Dyskinesia treatment, diagnosis, staging, causes, types, symptoms. Information and current news about clinical trials and trial-related data, Tardive Dyskinesia prevention, screening, research, statistics and other Tardive Dyskinesia related topics. We answer all your qestions about Tardive Dyskinesia.

Question: Does anyone know of a case of someone taking Abilify and getting tardive dyskinesia? It is the next Bipolar medication for me to try but I am terrified of getting tardive dyskinesia. I want to know the odds.

Answer: Your doctor can tell you. I have been on a drug now for seventeen years and my doctor test me every six months and so far no problems. You do have warning signs before you get it.... Tardive Dyskinesia (TD) is an involuntary neurological movement disorder caused by the use of neuroleptic drugs that are prescribed to treat certain psychiatric or gastrointestinal conditions. Long-term use of these drugs may produce biochemical abnormalities in the area of the brain known as the striatum. The reasons that some people who take these drugs may get Tardive Dyskinesia, and some people do not, is unknown. Tardive Dystonia is believed to be the more severe form of Tardive Dyskinesia.


Tardive Dyskinesia News

Mass High Tech

Synchroneuron focuses new funds on movement disorder drug
Mass High Tech
 

Synchroneuron raises $6M Series A; Rib-X scores $3M milestone; smoking makes ...

FierceBiotech
News | Follow @JohnCFierce > Waltham, MA-based Synchroneuron has rounded up $6 million in a Series A designed to support its work on a new treatment for Tardive dyskinesia. Story > Rib-X Pharmaceuticals says it snagged a $3 million milestone from ...
 

Neurocrine Biosciences Still Worth Watching

Seeking Alpha
As you may recall, last week the firm announced that its VMAT2 inhibitor product candidate, NBI-98854, has been granted Fast Track designation by the US Food and Drug Administration (FDA) for the treatment of neuroleptic-induced tardive dyskinesia.
 

Neurocine Biosciences Says That FDA Granted Fast Track Designation For NBI-98854

NASDAQ
... Biosciences Inc (NBIX) Wednesday stated that the US Food and Drug Administration or the FDA has granted Fast Track designation to its VMAT2 inhibitor product candidate NBI-98854 for the treatment of neuroleptic-induced tardive dyskinesia.
 

Executing And Creating Value, Neurocrine Biosciences Is Worth Watching

Seeking Alpha
Tardive dyskinesia is characterized by involuntary, repetitive movements of the extremities, lip smacking, grimacing, tongue protrusion, rapid eye movements or blinking, puckering and pursing of the lips, or impaired movement of the fingers.
 

Neurocrine Biosciences to Present at the 14th Annual BIO CEO & Investor Conference

MarketWatch (press release)
Our product candidates address some of the largest pharmaceutical markets in the world, including endometriosis, stress-related disorders, tardive dyskinesia, uterine fibroids, pain, diabetes, insomnia, and other neurological and endocrine-related ...
 

Medicure Reports Second Quarter 2012 Financial Results

MarketWatch (press release)
Subsequent to November 30, the Company announced the addition of a site in India for its ongoing Phase II Clinical Trial, TARDOXAL(TM) for the Treatment of Tardive Dyskinesia (TEND-TD). The Company anticipates interim results from the study will be ...
 

Medicure Provides Update on TEND-TD Phase II Clinical Trial

MarketWatch (press release)
... "Company") /quotes/zigman/4513555 CA:MPH +25.00% (pinksheets:MCUJ) is pleased to provide an update and announce the addition of a site in India for its ongoing Phase II Clinical Trial, TardoxalTM for the Treatment of Tardive Dyskinesia (TEND-TD).
 

Neurocrine Biosciences Announces Conference Call and Webcast To Present Fourth ...

PR Newswire (press release)
Our product candidates address some of the largest pharmaceutical markets in the world, including endometriosis, stress-related disorders, pain, tardive dyskinesia, uterine fibroids, diabetes, insomnia, and other neurological and endocrine-related ...
 

Research and Markets: Dyskinesia Therapeutics - Pipeline Assessment and Market ...

Business Wire (press release)
The dyskinesia therapeutics market is derived from the patient pool of Levodopa-Induced Dyskinesia (LID) and Tardive Dyskinesia (TD). LID is caused by levodopa, a widely used treatment option for Parkinson's disease (PD).